

=> d his

(FILE 'HOME' ENTERED AT 14:59:36 ON 28 JUL 2005)

FILE 'REGISTRY' ENTERED AT 15:00:13 ON 28 JUL 2005  
E LOTEPRREDNOL/CN

L1 2 S E3-E4

FILE 'CAPLUS' ENTERED AT 15:01:26 ON 28 JUL 2005  
L2 113 S L1 OR LOTEPRREDNOL OR ALREX OR CDDD(W)5604 OR HGP(W)1 OR LENOX

FILE 'REGISTRY' ENTERED AT 15:03:06 ON 28 JUL 2005  
E SALBUTAMOL/CN

L3 1 S E3

FILE 'CAPLUS' ENTERED AT 15:06:15 ON 28 JUL 2005  
L4 5206 S L3 OR AH(W)3365 OR AIROMIR OR ALBUTEROL OR EOLENE OR ETINOLI

FILE 'REGISTRY' ENTERED AT 15:08:48 ON 28 JUL 2005  
E REPROTEROL/CN

L5 1 S E3

FILE 'CAPLUS' ENTERED AT 15:09:59 ON 28 JUL 2005  
L6 169 S L5 OR D(W)1959 OR REPROTEROL

FILE 'REGISTRY' ENTERED AT 15:11:18 ON 28 JUL 2005  
E SALMETEROL/CN

L7 1 S E3

FILE 'CAPLUS' ENTERED AT 15:11:49 ON 28 JUL 2005  
L8 1025 S L7 OR GR(W)33343X OR SALMETEROL

FILE 'REGISTRY' ENTERED AT 15:12:28 ON 28 JUL 2005  
E FORMOTEROL/CN

L9 1 S E3


FILE 'CAPLUS' ENTERED AT 15:13:02 ON 28 JUL 2005  
L10 766 S L9 OR EFORMOTEROL OR FORMOTEROL OR OXIS  
L11 3 S L2(L) (L4 OR L6 OR L8 OR L10)

FILE 'EPFULL, FRFULL, GBFULL, PATDPAFULL, PCTFULL, RDISCLOSURE,  
USPATFULL, USPAT2' ENTERED AT 15:17:22 ON 28 JUL 2005  
L12 151 S L11 *checked*

FILE 'USPATFULL, USPAT2' ENTERED AT 15:20:08 ON 28 JUL 2005  
L13 70 S L11  
L14 17 S L13 AND (SZELENYI OR POPPE OR HEER OR ENGEL)  
*checked*

L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 129260-79-3 REGISTRY

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


CN Androsta-1,4-diene-17-carboxylic acid, 11,17-dihydroxy-3-oxo-, chloromethyl ester, (11 $\beta$ ,17 $\alpha$ )- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **Loteprednol**

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 82034-46-6 REGISTRY

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11 $\beta$ ,17 $\alpha$ )- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **Alrex**

CN **CDDD 5604**


CN **HGP 1**

CN **Lenoxin**

CN **Lotemax**

CN **Loteprednol etabonate**

CN **P 5604**




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN 1H-Purine-2,6-dione, 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN D 1959

CN **Reprotorol**



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN 1,3-Benzenedimethanol,  $\alpha$ 1-[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN m-Xylene- $\alpha$ , $\alpha'$ -diol,  $\alpha$ 1-[(tert-butylamino)methyl]-4-hydroxy- (8CI)

OTHER NAMES:

CN ( $\pm$ )-Albuterol

CN ( $\pm$ )-Salbutamol

CN  $\alpha$ 1-tert-Butylaminomethyl-4-hydroxy-m-xylene- $\alpha$ 1, $\alpha$ 3-diol

CN 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene- $\alpha$ 1, $\alpha$ 3-diol

CN 2-(tert-Butylamino)-1-[(4-hydroxy-3-hydroxymethyl)phenyl]ethanol

CN AH 3365

CN Airomir

CN Albuterol

CN dl-Albuterol

CN DL-N-tert-Butyl-2(4-hydroxy-3-hydroxymethylphenyl)2-hydroxyethylamine

CN dl-Salbutamol

CN Eolene

CN Etinoline

CN m-Xylene  $\alpha$ , $\alpha'$ -diol,  $\alpha$ -[(tert-butylamino)methyl]-4-hydroxy-

CN Proventil HFA

CN Proventil Inhaler

CN **Salbutamol**

CN Saventol

CN Spreor

CN Sultanol

CN Sultanol N


CN Ventalin Inhaler

CN Ventolin

CN Ventoline

CN Volmax

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[(2-(4-methoxyphenyl)-1-methylethyl)amino]ethyl]phenyl]-, (R\*,R\*)-(±)-

OTHER NAMES:


CN (±)Formoterol

CN Eformoterol

CN Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[(2-(4-methoxyphenyl)-1-methylethyl)amino]ethyl]phenyl]-, (R\*,R\*)-

CN **Formoterol**

CN Oxis



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, ( $\pm$ )-

OTHER NAMES:

CN GR 33343X

CN **Salmeterol**

=> s 12(1)(14 or 16 or 18 or 110)  
L11 3 L2(L) (L4 OR L6 OR L8 OR L10)

=> d ibib 1-3

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2005:346842 CAPLUS  
DOCUMENT NUMBER: 142:379418  
TITLE: Improvements in or relating to aerosol formulations comprising formoterol fumarate dihydrate  
INVENTOR(S): Mueller-Walz, Rudi  
PATENT ASSIGNEE(S): Jagotec A.-G., Switz.  
SOURCE: PCT Int. Appl., 23 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005034927	A2	20050421	WO 2004-IB3465	20041008
WO 2005034927	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-23685 A 20031009

L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2005:346830 CAPLUS  
DOCUMENT NUMBER: 142:397744  
TITLE: Aerosol formulations comprising formoterol fumarate dihydrate, ethanol and a steroid  
INVENTOR(S): Mueller-Walz, Rudi  
PATENT ASSIGNEE(S): Jagotec A.-G., Switz.  
SOURCE: PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005034911	A1	20050421	WO 2004-IB3481	20041008
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-23684 A 20031009

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:247172 CAPLUS

DOCUMENT NUMBER: 134:256899

TITLE: Combination of loteprednol and  $\beta_2$ -adrenoceptor agonists for the treatment of allergies and respiratory tract diseases

INVENTOR(S): Szelenyi, Istvan; Poppe, Hildegard; Heer, Sabine; Engel, Juergen

PATENT ASSIGNEE(S): Asta Medica Ag, Germany

SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022956	A2	20010405	WO 2000-EP9392	20000926
WO 2001022956	A3	20011011		
W: AU, BG, BR, BY, CA, CN, CZ, DZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19947235	A1	20010405	DE 1999-19947235	19990930
CA 2389111	AA	20010405	CA 2000-2389111	20000926
AU 2000079074	A5	20010430	AU 2000-79074	20000926
BR 2000014374	A	20020625	BR 2000-14374	20000926
EP 1216047	A2	20020626	EP 2000-969304	20000926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003510276	T2	20030318	JP 2001-526168	20000926
EE 200200163	A	20030415	EE 2002-163	20000926
PRIORITY APPLN. INFO.:			DE 1999-19947235	A 19990930
			WO 2000-EP9392	W 20000926

own PCT

instant  
Priority  
document

L13 ANSWER 41 OF 70 USPATFULL on STN  
ACCESSION NUMBER: 2002:262040 USPATFULL  
TITLE: Medical aerosol formulations  
INVENTOR(S): Keller, Manfred, Bad Krozingen, GERMANY, FEDERAL  
REPUBLIC OF  
Herzog, Kurt, Basel, SWITZERLAND  
PATENT ASSIGNEE(S): Jago Research AG, Muttenz, SWITZERLAND (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6461591	B1	20021008
	WO 9834595		19980813
APPLICATION INFO.:	US 1999-355883		19990804 (9)
	WO 1998-CH37		19980202
			19990804 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1997-248	19970205
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Choi, Frank	
LEGAL REPRESENTATIVE:	Selitto, Behr & Kim	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	932	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD beta-mimetics such as **salbutamol**, **formoterol**,  
**salmeterol**, fenoterol, clenbuterol, terbutaline, bambuterol,  
broxaterol, epinephrine, isoprenaline, orciprenaline, hexoprenaline,  
tulobuterol, **reprototerol**, bamethan etc.,  
DETD corticoids such as beclomethasone, betamethasone, ciclomethasone,  
dexamethasone, triamcinolone, budesonide, butixocort, ciclesonide,  
fluticasone, flunisolide, icomethasone, mometasone, tixocortol,  
**loteprednol** etc.,  
DETD 2.25 g of micronized ipratropium bromide and 11.25 g of micronized  
**salbutamol** are weighed into a pressure addition vessel. After  
sealing and evacuation thereof, 10.5 kg of HFA 227 which has previously.  
DETD 4.5 g of micronized oxitropium bromide and 0.675 g of micronized  
**formoterol** fumarate are weighed into a pressure addition vessel.  
After sealing and evacuation thereof, 10.5 kg of HFA 227 which has.

DETD . . . solution is mixed with 7.3 kg of HFA 227. The mixture obtained  
is added to 9.4 g of initially introduced **salbutamol** sulphate  
and adequately homogenized. After conclusion of the homogenization, the  
mixture is diluted with 2 kg of HFA 227 which. . .

CLM What is claimed is:  
. . . aerosol formulation according to claim 1, wherein the  
pharmaceutically active compound is a beta-mimetic selected from the  
group consisting of **salbutamol**, **formoterol**,  
**salmeterol**, fenoterol, clenbuterol, terbutaline, bambuterol,  
broxaterol, epinephrine, isoprenaline, orciprenaline, hexoprenaline,  
tulobuterol, **reprototerol**, bamethan, and pharmaceutically  
acceptable salts thereof.

. . . corticoid selected from the group consisting of beclomethasone,  
betamethasone, ciclomethasone, dexamethasone, triamcinolone, budesonide,  
butixocort, ciclesonide, fluticasone, flunisolide, icomethasone,  
**loteprednol**, and pharmaceutically  
acceptable salts thereof.

. . . does inhaler according to claim 10, wherein the pharmaceutically  
active compound is a beta-mimetic selected from the group consisting of

**salbutamol, formoterol, salmoterol, fenoterol,  
clenbuterol, terbutaline, bambuterol, broxaterol, epinephrine,  
isoprenaline, orciprenaline, hexoprenaline, tulobuterol,  
reprototerol, bamethan, and pharmaceutically acceptable salts  
thereof.**

**corticoid selected from the group consisting of beclomethasone,  
betamethasone, ciclomethasone, dexamethasone, triamcinolone, budesonide,  
butixocort, ciclesonide, fluticasone, flunisolide, icomethasone,  
mometasone, tixocortol, **loteprednol**, and pharmaceutically  
acceptable salts thereof.**